



Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Amended) A compound having the following structure:



including stereoisomers and pharmaceutically acceptable salts thereof,

wherein:



represents $\text{N}=\text{CH}$, $\text{NH}-\text{CH}_2$ or $\text{NH}-(\text{CH}_2)_2$;

X is N or CR_3 ;

R_1 is $-\text{CH}(\text{R}_4)(\text{R}_5)$;

R_2 is C_{1-6} alkyl;

R_3 is hydrogen or C_{1-6} alkyl;

R_4 is hydrogen, C_{1-6} alkyl, mono- or di(C_{3-6} cycloalkyl)methyl, C_{3-6} cycloalkyl, C_3 -

alkenyl, hydroxy C_{1-6} alkyl, C_{1-6} alkylcarbonyloxy C_{1-6} alkyl, or C_{1-6} alkyloxy C_{1-6} alkyl, and


R_5 is C_{1-8} alkyl, mono- or di(C_{3-6} cycloalkyl)methyl, Ar^1CH_2 , C_{3-6} alkenyl, C_{1-6} alkyloxy C_{1-6} alkyl, hydroxy C_{1-6} alkyl, thienylmethyl, furanylmethyl, C_{1-6} alkylthio C_{1-6} alkyl, morpholinyl, mono- or di(C_{1-6} alkyl)amino C_{1-6} alkyl, di(C_{1-6} alkyl)amino, C_{1-6} alkylcarbonyl C_{1-6} alkyl, C_{1-6} alkyl substituted with imidazolyl, $-CH_2Obenzyl$, or a radical of the formula $-(C_{1-6}alkanediyl)-O-CO-Ar^1$,

or R_4 and R_5 taken together with the carbon atom to which they are bonded form a C_{5-8} cycloalkyl optionally substituted with one or more substituents independently selected from C_{1-6} alkyl;

Ar is phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6} alkyl, trifluoromethyl, cyano, C_{1-6} alkyloxy, benzyloxy, C_{1-6} alkylthio, nitro, amino, and mono- or di(C_{1-6} alkyl)amino; or an aromatic C_{3-12} heterocycle optionally substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6} alkyl, trifluoromethyl, hydroxy, cyano, C_{1-6} alkyloxy, benzyloxy, C_{1-6} alkylthio, nitro, amino, mono- or di(C_{1-6} alkyl)amino, and piperidinyl; and


Ar^1 is phenyl, pyridinyl, or phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C_{1-6} alkyl, C_{1-6} alkyloxy, di(C_{1-6} alkyl)amino C_{1-6} alkyl, trifluoromethyl and C_{1-6} alkyl substituted with morpholinyl.

2. (Amended) The compound of claim 1 having the structure:



3. (Canceled)

4. (Amended) The compound of claim 1 having the structure:



- 5.-7. (Canceled)

8. (Original) The compound of claim 1 wherein Ar is 2,4-dichlorophenyl.

9. (Original) The compound of claim 1 wherein Ar is 2-chloro-4-methyl-phenyl.

10. (Original) The compound of claim 1 wherein Ar is 2-methyl-4-chloro-phenyl.

11. (Original) The compound of claim 1 wherein Ar is 2,4,6-trimethyl-phenyl.

12. (Original) The compound of claim 1 wherein Ar is 2-chloro-4-methoxy-phenyl.

13. (Original) The compound of claim 1 wherein Ar is 2-methyl-4-methoxy-phenyl.

14. (Original) The compound of claim 1 wherein Ar is 2,4-dimethoxy-phenyl.
 15. (Original) The compound of claim 1 wherein Ar is 4-dimethylamino-2-methyl-3-pyridyl.
 16. (Original) The compound of claim 1 wherein Ar is 4-dimethylamino-6-methyl-3-pyridyl.
 17. (Original) The compound of claim 1 wherein Ar is 4-dimethylamino-3-pyridyl.
 18. (Original) The compound of claim 1 wherein R₁ is -CH(n-propyl)₂.
 19. (Original) The compound of claim 1 wherein R₁ is -CH(n-propyl)(CH₂OCH₃).
 20. (Original) The compound of claim 1 wherein R₁ is -CH(benzyl)(CH₂OCH₃).
 21. (Original) The compound of claim 1 wherein R₁ is -CH(CH₂OR)₂ and each occurrence of R is independently selected from C₁₋₆alkyl.
 22. (Original) The compound of claim 1 wherein R₁ is -CH(CH₂OR)(ethyl) and each occurrence of R is independently selected from C₁₋₆alkyl.
 23. (Original) The compound of claim 1 wherein R₁ is -CH(CH₂OR)(n-butyl) and each occurrence of R is independently selected from C₁₋₆alkyl.
-

24. (Original) The compound of claim 1 wherein R_1 is $-\text{CH}(\text{CH}_2\text{OR})(\text{tert-butyl})$ and each occurrence of R is independently selected from $\text{C}_{1-6}\text{alkyl}$.

25. (Original) The compound of claim 1 wherein R_1 is $-\text{CH}(\text{CH}_2\text{OR})(4\text{-chloro-benzyl})$ and each occurrence of R is independently selected from $\text{C}_{1-6}\text{alkyl}$.

26. (Original) The compound of claim 1 wherein R_1 is $-\text{CH}(\text{CH}_2\text{OR})(\text{CH}_2\text{CH}_2\text{SCH}_3)$ and each occurrence of R is independently selected from $\text{C}_{1-6}\text{alkyl}$.

27. (Original) The compound of claim 1 wherein R_1 is $-\text{CH}(\text{CH}_2\text{CH}_3)(\text{CH}_2\text{Obenzyl})$.

28. (Original) The compound of claim 1 wherein R_2 is methyl.

29. (Original) The compound of claim 1 wherein R_2 is ethyl.

30. (Amended) A ~~pharmaceutical~~ composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.

31. (Amended) A method for treating stroke, anxiety, depression or irritable bowel syndrome ~~a disorder manifesting hypersecretion of CRF~~ in a warm-blooded animal, comprising administering to the animal an effective amount of the ~~pharmaceutical~~ composition of claim 30.

32. (Original) The method of claim 31 wherein the disorder is stroke.

33. (Original) The method of claim 31 wherein the disorder is anxiety.

34. (Original) The method of claim 31 wherein the disorder is depression.

35. (Original) The method of claim 31 wherein the disorder is irritable bowel syndrome.